A Wearable Device That Uses Electric Fields to Treat Pancreatic Cancer
Optune Pax is an FDA-approved wearable cancer treatment device that delivers tuned electric fields through adhesive patches on the abdomen to disrupt pancreatic cancer cell division while patients go about their daily lives.
Photo source:
Optunepax
Why Optune Pax Matters
Locally
advanced pancreatic cancer is one of the most difficult cancers to treat. It
accounts for a significant portion of pancreatic cancer diagnoses, and
treatment options have remained largely unchanged for decades. Standard care
has relied primarily on chemotherapy, with limited alternatives for patients
whose tumors cannot be surgically removed. Novocure, a global oncology company
headquartered in Baar, Switzerland, developed Optune Pax as a fundamentally
different approach. Rather than using drugs or radiation, the device delivers
alternating electric fields directly into the tumor through the skin. The FDA
approved Optune Pax as the first device of its kind for the treatment of adult
patients with locally advanced pancreatic cancer.
The
approval was based on results from a large clinical trial called PANOVA-3, an
international, randomized study involving 571 patients. The trial evaluated
Optune Pax used together with chemotherapy drugs gemcitabine and
nab-paclitaxel, compared to patients receiving the same chemotherapy drugs
alone. Results showed that patients treated with Optune Pax and chemotherapy
demonstrated significant improvements in overall survival compared to those on
chemotherapy alone. The findings were published in the Journal of Clinical
Oncology and selected as a top presentation at a major oncology conference.
How This Wearable Cancer Treatment Device Works
Optune
Pax uses a technology called Tumor Treating Fields, or TTFields. These are
low-intensity, alternating electric fields that are tuned to a specific
frequency matched to pancreatic cancer cells. When applied, the fields
interfere with the process of cell division, called mitosis, that cancer cells
rely on to multiply. By disrupting this process, TTFields can slow down or stop
cancer cell division and may even destroy the cells. Because healthy cells
divide at different rates and have different electrical properties than cancer
cells, TTFields are designed to target tumor cells without significantly
affecting surrounding healthy tissue. Preclinical data also suggest that
TTFields may help activate the immune system to further fight the disease.
The
device consists of three components. Transducer arrays, which are electrically
insulated adhesive patches, are placed on the patient's abdomen over the tumor
area. These arrays connect to a portable electric field generator that produces
the TTFields at preset, unalterable parameters set by the manufacturer. The
generator is carried in a specially designed bag. Patients wear the device
while continuing their daily activities, receiving continuous treatment as they
move, work, or rest. Optune Pax is used alongside chemotherapy, not as a
replacement for it.
Exploring the Clinical Results of Optune Pax
The
PANOVA-3 trial measured several outcomes beyond overall survival. Patients
treated with Optune Pax and chemotherapy experienced six additional months
before their pain progressed compared to those on chemotherapy alone. The trial
also reported significant delays in the need for opioid pain medication among
patients in the Optune Pax group. Across multiple quality-of-life measures,
including digestive problems and fatigue, patients using the device
demonstrated improvement in maintaining their daily functioning for a longer
period.
The
device was well tolerated in the trial. Adding Optune Pax to chemotherapy did
not worsen the side effects typically associated with the chemotherapy drugs
themselves. The most common device-related side effects were mild to moderate
skin reactions beneath the transducer arrays, including irritation, redness,
rash, and in some cases open sores. Patients may also experience warmth and
tingling beneath the arrays during treatment. Novocure provides a dedicated
support program called MyNovocure that connects patients with resources, a
doctor locator, and community support throughout their treatment journey.
Who Can and Cannot Use Optune Pax
Optune
Pax is indicated for adult patients with locally advanced pancreatic cancer and
is used together with gemcitabine and nab-paclitaxel as a first-line treatment.
It should only be used after the patient receives training from qualified
medical personnel who have completed a training course provided by Novocure.
Patients must use the specific components included in the Optune Pax Treatment
Kit and should not substitute any parts.
The
device is not suitable for everyone. Patients with electrical implants should
not use Optune Pax because the interaction between the device and implanted
electronics has not been tested and may cause the implant to malfunction.
Patients with a known sensitivity to conductive gels, such as those used on ECG
stickers, may experience increased skin reactions. The device should not be
used during pregnancy, and women of childbearing potential must use birth
control while on treatment. The transducer arrays must be kept dry, and
patients with underlying skin conditions in the treatment area should discuss
with their doctor whether this may interfere with treatment.
Where Tumor Treating Fields Fit in Cancer Treatment
TTFields
technology is not limited to pancreatic cancer. Novocure has previously
received FDA approval for TTFields devices in the treatment of glioblastoma, a
type of brain cancer, and metastatic non-small cell lung cancer. Across all
three approved indications, the company reports more than 4,400 active patients
currently receiving TTFields therapy worldwide. Novocure generated $655 million
in net revenues in its most recent full fiscal year, with patients treated
across the United States, Germany, France, Japan, and other markets. The device
also received CE Mark approval for pancreatic cancer, opening a regulatory
pathway for European markets.
The
broader significance of Optune Pax lies in what it represents as a treatment
modality. Most cancer therapies work through chemical or biological mechanisms,
using drugs that circulate through the body to target cancer cells. TTFields
take a biophysical approach, using electric fields applied externally to
physically interfere with tumor cell division at the site of the disease.
Whether this approach expands to additional cancer types will depend on ongoing
clinical trials and regulatory outcomes. For patients with locally advanced
pancreatic cancer, Optune Pax provides a treatment option that did not exist
before, used alongside existing chemotherapy to extend survival and maintain
quality of life.
You have exceeded your free limits for viewing our premium content
Please subscribe to have unlimited access to our innovations.
Get The Latest In Innovation
Join Our Newsletter
Where bold ideas find bold readers.
